Levetiracetam Accord Healthcare (Levetiracetam)

The drug binds to the synaptic vesicle protein SV2A, which regulates neurotransmitter release. This binding modulates synaptic transmission, reduces neuronal hyper‑excitability, and limits the excessive release of excitatory neurotransmitters such as glutamate, thereby helping to prevent seizure initiation and spread.

The appropriate dose of Levetiracetam is individualized by the prescribing clinician based on factors such as the patient’s age, weight, renal function, seizure type, and response to therapy. Dosage adjustments may be required for patients with impaired kidney function or those taking interacting medications.

Data on Levetiracetam use in pregnancy and lactation are limited. Clinicians should weigh the potential benefits against possible risks and consider alternative therapies when appropriate. If treatment is necessary, it should be managed by a specialist with close monitoring of both mother and infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details and any required import documentation.

Levetiracetam offers a distinct mechanism by targeting SV2A, which differs from sodium‑channel blockers or GABA‑enhancers. It has a relatively low potential for drug‑drug interactions and does not require routine therapeutic drug monitoring, making it a convenient option for many patients compared with older antiepileptics.

Store Levetiracetam tablets at ambient temperature, preferably below 25 °C. Keep the product in its original container, protect it from moisture and direct sunlight, and ensure the packaging remains sealed until use to maintain stability and potency.

Levetiracetam is taken orally, usually as a tablet swallowed with water. It can be administered with or without food, and the dosing schedule (once, twice or thrice daily) is determined by the prescriber based on the individual’s therapeutic needs.

Serious adverse events include severe allergic reactions such as Stevens‑Johnson syndrome, significant mood alterations including depression or suicidal ideation, and hematologic abnormalities like neutropenia. Patients should be instructed to seek immediate medical attention if they experience rash, mood changes, or signs of infection.

Levetiracetam is contraindicated in individuals with known hypersensitivity to the drug or any of its excipients. Caution is advised for patients with severe renal impairment, uncontrolled psychiatric conditions, or those taking medications that markedly reduce its plasma levels without appropriate dose adjustments.